A detailed history of Contrarius Group Holdings LTD transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Contrarius Group Holdings LTD holds 126,470 shares of BEAM stock, worth $2.26 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
126,470
Holding current value
$2.26 Million
% of portfolio
0.17%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025

BUY
$19.53 - $34.09 $2.47 Million - $4.31 Million
126,470 New
126,470 $2.47 Billion

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.26B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Contrarius Group Holdings LTD Portfolio

Follow Contrarius Group Holdings LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Contrarius Group Holdings LTD, based on Form 13F filings with the SEC.

News

Stay updated on Contrarius Group Holdings LTD with notifications on news.